BIOLINERX     Print Page  Close Window

SEC filings
6-K
BIOLINERX LTD. filed this Form 6-K on 03/23/2015
Entire Document
 
5

 
 
BioLineRx Ltd.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
 
   
Year ended December 31,
   
Convenience
 translation
 into USD
 
   
2012
   
2013
   
2014
   
2014
 
   
NIS in thousands
   
In thousands
 
                         
RESEARCH AND DEVELOPMENT EXPENSES, NET
    (64,304 )     (44,057 )     (42,443 )     (10,914 )
SALES AND MARKETING EXPENSES
    (3,227 )     (4,101 )     (5,685 )     (1,462 )
GENERAL AND ADMINISTRATIVE EXPENSES
    (14,026 )     (13,225 )     (13,591 )     (3,495 )
                                 
OPERATING LOSS
    (81,557 )     (61,383 )     (61,719 )     (15,871 )
NON-OPERATING INCOME, NET
    3,958       4,191       10,948       2,815  
FINANCIAL INCOME
    8,819       2,600       12,754       3,280  
FINANCIAL EXPENSES
    (7,490 )     (6,846 )     (1,603 )     (412 )
                                 
NET LOSS AND COMPREHENSIVE LOSS
    (76,270 )     (61,438 )     (39,620 )     (10,188 )
                                 
   
NIS
   
USD
 
LOSS PER ORDINARY SHARE – BASIC AND DILUTED
    (0.45 )     (0.27 )     (0.12 )     (0.03 )
                                 
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE
    169,404,730       224,885,157       324,338,834       324,338,834